OverviewSuggest Edit

Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is focused on diseases affecting the back of the eye, or retina. It provides ILUVIEN (fluocinolone acetonide intravitreal implant) for the treatment of diabetic macular edema (DME).
TypePublic
Founded2003
HQAlpharetta, US
Websitealimerasciences.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Jan 2020)122(-1%)
Job Openings17
Revenue (FY, 2019)$53.9 M(+15%)
Share Price (Jun 2020)$6.1 (-4%)
Cybersecurity ratingBMore

Key People/Management at Alimera Sciences

Ken Greene

Ken Greene

CSO
Rick Eiswirth

Rick Eiswirth

Director, President and Chief Executive Officer
Susan Caballa

Susan Caballa

Sr. Vice President, Regulatory & Medical Affairs
Brian Halak

Brian Halak

Director
Philip Ashman

Philip Ashman

Chief Operating Officer Senior Vice President, Commercial Operations Europe
Phil Jones

Phil Jones

Chief Financial Officer
Show more

Alimera Sciences Office Locations

Alimera Sciences has offices in Alpharetta, Berlin, Lisboa and Hampshire
Alpharetta, US (HQ)
6120 Windward Pkwy #290
Berlin, DE
21 Cicerostraße
Lisboa, PT
Av. Dom João II
Hampshire, GB
Wellesley Rd
Show all (4)

Alimera Sciences Financials and Metrics

Alimera Sciences Revenue

Alimera Sciences's revenue was reported to be $53.94 m in FY, 2019
USD

Revenue (Q1, 2020)

14.5m

Net income (Q1, 2020)

(1.2m)

EBIT (Q1, 2020)

218.0k

Market capitalization (29-Jun-2020)

30.8m

Closing stock price (29-Jun-2020)

6.1

Cash (31-Mar-2020)

12.2m

EV

60.0m
Alimera Sciences's current market capitalization is $30.8 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

1.9m8.4m22.4m34.3m35.9m47.0m53.9m

Revenue growth, %

350%166%53%

Cost of goods sold

1.9m1.4m1.8m2.3m3.4m4.7m

Gross profit

9.0k7.0m20.7m32.0m32.5m42.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

179.0k758.0k2.1m2.2m2.4m3.9m5.8m6.9m5.8m9.6m8.3m6.6m10.4m9.8m9.8m10.9m11.1m12.9m10.9m12.9m14.5m

Cost of goods sold

11.0k57.0k564.0k376.0k372.0k283.0k376.0k634.0k378.0k556.0k486.0k587.0k769.0k1.0m1.3m1.1m965.0k1.6m

Gross profit

168.0k701.0k1.5m1.8m2.0m3.7m5.4m6.3m5.4m9.0m7.8m6.0m9.6m8.7m8.5m9.8m10.2m11.3m

Gross profit Margin, %

94%92%73%83%85%93%93%91%93%94%94%91%93%89%87%90%91%88%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

33.1m49.6m12.6m76.7m31.1m31.0m24.1m13.0m9.4m

Accounts Receivable

500.0k850.0k9.8m13.8m11.4m17.3m19.3m

Prepaid Expenses

692.0k2.0m3.5m3.2m2.7m2.3m2.1m2.6m

Inventories

719.0k1.8m1.7m1.6m446.0k1.5m2.4m1.4m
Quarterly
USDQ2, 2011

Financial Leverage

1.3 x
Show all financial metrics

Alimera Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Alimera Sciences Online and Social Media Presence

Embed Graph

Alimera Sciences News and Updates

Alimera Sciences Pre-Announces Expected Top Line Revenue for Q1 2020 and Provides COVID-19 Business Update

ATLANTA, April 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announces top-line revenue …

Proliferative Diabetic Retinopathy Industry Insights, 2020-2025 - Key Players are Novartis, Regeneron Pharma, Allergan, Roche, Oxurion, Alimera Sciences, BCN Peptides, Glycadia Pharma and Kowa Group

DUBLIN, March 2, 2020 /PRNewswire/ -- The "Proliferative Diabetic Retinopathy Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The Proliferative Diabetic Retinopathy Market is expected to register a CAGR of 9.4% during the...

Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

ATLANTA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, President and Chief Exec…

Alimera Sciences Announces Board’s Approval of Reverse Stock Split Ratio

ATLANTA, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will effect a one-for-15 reverse stock split (reverse s…

Alimera Sciences Announces Equity Purchase Agreement for up to $20 Million with Lincoln Park Capital

ATLANTA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has entered into a $20.0 million common stock purchase …
Show more

Alimera Sciences Blogs

Alimera Sciences Terminates Equity Purchase Agreement

ATLANTA , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has terminated its $20.0 million common stock purchase

Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York

Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York Content Import Tue, 11/05/2019 - 08:31 Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York Nov 5, 2019 This rele…

Alimera Sciences to Report Third Quarter 2019 Financial Results on Tuesday, October 29, 2019 and Provide Corporate Update

Conference Call to be held Wednesday, October 30, 2019 at 9:00am Eastern Time ATLANTA , Oct. 23, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis

Company continues strategy to grow the use of ILUVIEN internationally through geographic expansion and further penetration into existing markets   ATLANTA , Oct. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of

Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019

Consolidated net revenue expected to exceed $12.8 million   ATLANTA , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces

Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting

Data highlight ILUVIEN’s advantages as the only therapy that consistently treats diabetic macular edema (DME) for up to 3 years   ATLANTA , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription
Show more

Alimera Sciences Frequently Asked Questions

  • When was Alimera Sciences founded?

    Alimera Sciences was founded in 2003.

  • Who are Alimera Sciences key executives?

    Alimera Sciences's key executives are Ken Greene, Rick Eiswirth and Susan Caballa.

  • How many employees does Alimera Sciences have?

    Alimera Sciences has 122 employees.

  • What is Alimera Sciences revenue?

    Latest Alimera Sciences annual revenue is $53.9 m.

  • What is Alimera Sciences revenue per employee?

    Latest Alimera Sciences revenue per employee is $442.2 k.

  • Who are Alimera Sciences competitors?

    Competitors of Alimera Sciences include BeyondSpring, GT Biopharma and Cidara Therapeutics.

  • Where is Alimera Sciences headquarters?

    Alimera Sciences headquarters is located at 6120 Windward Pkwy #290, Alpharetta.

  • Where are Alimera Sciences offices?

    Alimera Sciences has offices in Alpharetta, Berlin, Lisboa and Hampshire.

  • How many offices does Alimera Sciences have?

    Alimera Sciences has 4 offices.